Compare KraneShares CSI China Internet ETF (KWEB) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares CSI China Internet ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? KraneShares CSI China Internet ETF trades at $24.9 (market cap $4.37B), while Vertex Pharmaceuticals Incorporated trades at $511.21 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 29.2× KraneShares CSI China Internet ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares CSI China Internet ETF for 57 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| KWEB | VRTX | |
|---|---|---|
Market Cap | $4.37B | $127.55B |
Volume | 13,393,361 | 1,487,944 |
Sector | Sector/Thematic | Health |
52-Week High | $41.35 | $557.96 |
52-Week Low | $23.63 | $407.37 |
Typical Hold Time | 57 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KWEB, the KraneShares CSI China Internet ETF, trades at $24.87, up 2.22% over the past 24 hours. Technical indicators show a bearish trend with moving averages signaling sell, while oscillators are neutral. Recent news highlights institutional activity, including a stake reduction by Tidal Investments LLC and an increase by HSBC Holdings PLC, amid ongoing U.S.-China trade dynamics and economic data releases.
The outlook for KWEB is clouded by geopolitical tensions and economic headwinds in China, though corporate profit growth offers a potential catalyst. Key risks include trade policy shifts and weak domestic consumption. Investors should weigh institutional movements against broader market sentiment for balanced exposure.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
